AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
Press Release: Lowering the out-of-pocket costs of blood glucose testing strips can improve diabetes patients’ persistence with home monitoring, according to an article in the August 2017 issue of the Journal of Managed Care & Specialty Pharmacy (JMCP).
Conclusions reached in a recent New York Times article on outcomes-based contracting are premature, if not inaccurate, stated Academy of Managed Care Pharmacy (AMCP) CEO Susan A. Cantrell, RPh, CAE, adding, “It’s still the early innings for outcomes-based, or value-based, contracting for prescription drugs, and therefore, too soon to dismiss.”
AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (Part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
On behalf of the Academy of Managed Care Pharmacy (AMCP), I wanted to take this opportunity to express our strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (H.R. 2212), bipartisan legislation to increase competition and patient access to safe and affordable generic and biosimilar medicines.
The Friends of the National Quality Forum (NQF) strongly urge you to support continuing the currently authorized $30 million in annual Medicare funding for NQF and quality and performance measurement. NQF’s work is vital to advancing our national commitment to safer, more effective care.